Peter Heerma sold $18M of TVTX
EVP, CHIEF COMMERCIAL OFFICER at Travere Therapeutics, Inc.. 283,189 shares at an average of $63.06, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleOfficer
- +25Trade size$17.9M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001789617-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +39,283 | $26.88 | $1.1M | 181,349 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +1,381 | $22.40 | $31k | 182,730 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +36,526 | $8.93 | $326k | 219,256 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -71,938 | $62.05 | $4.5M | 147,318 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -27,421 | $62.59 | $1.7M | 119,897 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -1,400 | $63.65 | $89k | 118,497 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -1,431 | $65.31 | $93k | 117,066 | 25 d ago |
| Sep 16, 2026 | MOption exercise Common Stock10b5-1 | +100,000 | $11.25 | $1.1M | 217,066 | 25 d ago |
| Sep 16, 2026 | MOption exercise Common Stock10b5-1 | +55,000 | $15.46 | $850k | 272,066 | 25 d ago |
| Sep 16, 2026 | MOption exercise Common Stock10b5-1 | +17,717 | $26.88 | $476k | 289,783 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -93,604 | $63.25 | $5.9M | 196,179 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -79,113 | $63.65 | $5.0M | 117,066 | 25 d ago |
| Sep 17, 2026 | MOption exercise Common Stock10b5-1 | +8,282 | $22.40 | $186k | 125,348 | 25 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -8,282 | $65.07 | $539k | 117,066 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -39,283 | $0.00 | $0 | 18,217 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -1,381 | $0.00 | $0 | 53,119 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -36,526 | $0.00 | $0 | 28,474 | 25 d ago |
| Sep 16, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -55,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -17,717 | $0.00 | $0 | 500 | 25 d ago |
| Sep 17, 2026 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -8,282 | $0.00 | $0 | 44,837 | 25 d ago |
Related signals
Other insiders at Travere Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Travere Therapeutics, Inc. | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | $335k 5,375 shares | -11% | |
| 37Weak | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $3.1M 50,508 shares | -37% | |
| 50Moderate | Travere Therapeutics, Inc. | Eric M Dube CHIEF EXECUTIVE OFFICER | $25M 400,000 shares | -76% | |
| 30Weak | Travere Therapeutics, Inc. | Jula Inrig EVP, Head of R&D & CMO | $2.8M 44,674 shares | -31% | |
| 30Weak | Travere Therapeutics, Inc. | Elizabeth E Reed Chief Legal Officer and GC | $2.3M 37,500 shares | -26% | |
| 40Moderate | Travere Therapeutics, Inc. | William E. Rote Chief Research Officer | $13M 209,048 shares | -108% | |
| 25Weak | Travere Therapeutics, Inc. | Jeffrey A Meckler director | $1.3M 20,000 shares | -18% | |
| 43Moderate | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $43k 642 shares | -1% | |
| 2Weak | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $11k 573 shares | -1% | |
| 2Weak | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $8,136 470 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.